Revolution Medicines officer sells $353,449 in shares

In a significant move, Anthony Mancini, the Chief Global Commercialization Officer at Revolution Medicines Inc. (NASDAQ:RVMD), disposed of 1,774 shares of the company's common stock, amounting to $353,449. The sales took place on September 16, 2026, with the shares being traded at prices between $195.0521 and $199.3032 per share.

The surge in the stock price, which has increased by 322% over the past year and 95% in the last six months, has led to the stock being classified as overvalued, according to InvestingPro data. The transactions were carried out under a Rule 10b5-1 trading plan, adopted on June 15, 2026, to meet tax withholding requirements upon the vesting of restricted stock units.

After the transactions, Mancini still holds 42,116 shares, including 39,575 restricted stock units. Revolution Medicines has recently garnered substantial attention following the FDA approval of its drug Rasonque, also known as daraxonrasib. This approval has prompted several financial institutions to revise their stock price targets.

Morgan Stanley initiated coverage with an overweight rating, while Needham increased its price target to $275. UBS adjusted its target to $265, and H.C. Wainwright raised its target to $280. These developments highlight the positive reception of Rasonque's approval and its potential impact on Revolution Medicines' future.